1. Generics Bulletin
  2. >>Preview

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

What's Next Image
Norstella/Citeline

Sandoz is set to break new ground in May, introducing the first US biosimilars to Amgen’s denosumab brands, Prolia and Xgeva, via a patent-litigation settlement agreement with the originator.

On 31 May, Sandoz is expected to launch its Wyost (denosumab-bddz) and Jubbonti (denosumab-bddz) rivals to Amgen’s Xgeva and Prolia brands respectively, following a deal penned...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Preview

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

What’s Next? Five Things To Look Out For In April

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for April 2025.

What’s Next? Five Things To Look Out For In March

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for March 2025.

What’s Next? Five Things To Look Out For In February

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for February 2025.

More from Biosimilars

Samsung Bioepis Heads For Spin Out To Unlock ‘Hidden Value’

 
• By Dean Rudge

Samsung Biologics will retain solely its significant CDMO business, eliminating a perceived conflict of interest, as it pursues an equity spin-off for its biosimilars business Samsung Bioepis.

Amgen And Samsung Soliris Biosimilars Skirt UK Infringement On Claim Construction

 
• By Dean Rudge

Just days after a court in Canada barred Amgen’s Soliris biosimilar until patent expiry in 2027, a UK High Court has handed a favorable ruling to the California-based firm and Samsung Bioepis, ruling that their products do not infringe a patent shielding the branded treatment for paroxysmal nocturnal hemoglobinuria.

Formycon Hopes Stelara Biosimilar Sales To Pull Through FY2025 As Q1 Revenues Slump

 
• By Urtė Fultinavičiūtė

Formycon said it predicted low earnings in the first quarter of 2025, after enjoying milestone payments last year. Now, the pressure is on the growing biosimilars portfolio to pull the company through this year.